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Abstract
Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide, designed to interact with a novel
cell surface receptor, composed of the classical erythropoietin (EPO) receptor disulfide linked to the beta com-
mon receptor. pHBSP has the cytoprotective effects of EPO without stimulating erythropoiesis. Effects on early
cerebral hemodynamics and neurological outcome at 2 weeks post-injury were compared in a rat model of mild
cortical impact injury (3m/sec, 2.5 mm deformation) followed by 50 min of hemorrhagic hypotension (MAP
40 mm Hg for 50 min). Rats were randomly assigned to receive 5000 U/kg of EPO, 30 lg/kg of pHBSP, or an
inactive substance every 12 h for 3 days, starting at the end of resuscitation from the hemorrhagic hypotension,
which was 110 min post-injury. Both treatments reduced contusion volume at 2 weeks post-injury, from
20.8 – 2.8 mm3 in the control groups to 7.7 – 2.0 mm3 in the EPO-treated group and 5.9 – 1.5 mm3 in the pHBSP-
treated group ( p = 0.001). Both agents improved recovery of cerebral blood flow in the injured brain following
resuscitation, and resulted in more rapid recovery of performance on beam balancing and beam walking tests.
These studies suggest that pHBSP has neuroprotective effects similar to EPO in this model of combined brain
injury and hypotension. pHBSP may be more useful in the clinical situation because there is less risk of
thrombotic adverse effects.
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Introduction
Erythropoietin (EPO) is a potentially attractive neuro-protective agent following traumatic brain injury (TBI). In
experimental models, EPO has improved outcome after TBI
(Brines et al., 2000; Cherian et al., 2007), subarachnoid hem-
orrhage (Grasso, 2001), stroke (Wang et al., 2004), global is-
chemia (Catania et al., 2002), and other central nervous system
disorders. EPO has been found to improve outcome from
spinal cord injury and ischemia in some experimental studies
but not in others (Celik et al., 2002; Gorio et al., 2002; Mann
et al., 2008; Pinzon et al. 2008).
In experimental TBI studies, EPO has been shown to have
neuroprotective effects when given early post-injury, and to
have effects that enhance neurological recovery even when
given at later times after injury (Lu et al., 2005). The early
neuroprotective mechanisms are probably complex, involv-
ing anti-inflammatory, anti-apoptotic, and vascular actions
(Siren et al., 2001; Villa et al., 2003). The time window for EPO-
induced neuroprotection after experimental TBI is at least 6 h
post-injury (Brines et al., 2000; Cherian et al., 2007). The late
mechanisms of EPO that may enhance neurological recovery
may include both neurogenesis and angiogenesis (Lu et al.,
2005; Marti et al., 2000; Wang et al., 2004). The time window
for these delayed actions of EPO is not clearly defined, but
doses given as late as 24 h post-injury significantly enhance
neurological recovery in stroke and TBI models (Lu et al. 2005;
Wang et al. 2004).
Despite these positive features observed in the laboratory,
it has been difficult to translate EPO into the clinical setting
for TBI and other neurological disorders, because the doses
of EPO required for neuroprotection and enhancement of
neurological recovery have some potentially adverse effects
in patients. Almost all studies of EPO in critically ill
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patients and in postoperative patients have shown an in-
creased risk of thrombosis with EPO administration (Cor-
win et al., 2007; Dicato et al., 2008). The most serious
complications associated with EPO occurred in a recent
trial, in which the patients given EPO in doses of 40,000 U/
day · 3 days after stroke, and had a higher rate of intra-
cranial hemorrhage and a higher mortality rate than control
patients (Ehrenreich et al., 2009). These complications may
have resulted from an interaction with tissue plasminogen
activator (t-PA) which was also given in 63% of the patients
in the trial, in some cases outside of the therapeutic win-
dow for t-PA. Subsequent studies in experimental models
have demonstrated that the combination of t-PA and EPO
given at 6 h after middle cerebral artery occlusion can ex-
acerbate t-PA-induced brain hemorrhage ( Jia et al., 2010).
Zechariah and associates found that the combination of
EPO and t-PA immediately after reperfusion following
90 min of middle cerebral artery occlusion caused increased
vascular permeability and extracellular matrix breakdown
(Zechariah et al., 2010).
The dose of 40,000 U, which is approved for human use, is
at the lower limit of the doses that have been effective in
experimental models. Because of the risk of thrombotic
events, it may not be possible to give EPO in sufficient doses to
improve neurological outcome without increasing the risk of
life-threatening complications. For military and pre-hospital
applications, the need to refrigerate EPO is another significant
limitation for translation of the therapy.
Leist and associates demonstrated that the hematopoietic
and tissue protective effects of EPO can be separated (Leist
et al., 2004). A novel cell surface receptor, composed of the
classical EPO receptor (EPOR) disulfide linked to the beta
common receptor, CD131, may mediate the non-hematopoietic
effects of EPO (Brines et al., 2004). Based on these findings,
an 11-amino acid synthetic peptide was developed that
mimics the 3-D structure of EPO and retains EPO’s neuro-
protective activities, but not the hematopoietic actions that are
responsible for the adverse effects of EPO. Helix B surface
peptide (-HBSP) is a linear peptide containing the amino acids
from the aqueous face of helix B (amino acids 58–85) of
erythropoietin (QEQLERALNSS). A modification of the
N-terminal Q to pyroglutamate (U) for stabilization, results in
a peptide (UEQLERALNSS) that can be stored for 2 years at
4C or up to 12 months at 25C. Therefore, pyroglutamate
helix B (pHBSP) may have significant advantages over EPO as
a therapeutic agent for use in the pre-hospital setting and on
the battlefield.
The purpose of this study was to evaluate the neuropro-
tective effects of pHBSP compared to EPO in a model of mild
TBI complicated by hemorrhagic shock. In addition, the effect
of pHBSP and EPO on early cerebral blood flow was studied,
as one potential mechanism for neuroprotective effects.
Methods
To accomplish these goals, an acute experiment of early
cerebral hemodynamics and a chronic experiment with be-
havioral and histological endpoints were performed. The
model for the two parts of the study was a mild cortical impact
injury followed by a period of hemorrhagic hypotension in
rats. The experiments were approved by the Baylor Institu-
tional Animal Care and Use Committee.
Experimental model
Long Evans rats weighing an average of 371 – 8 g were used
for the experiments. The animals were anesthetized with
isofluorane in oxygen, intubated, and ventilated to maintain
normal arterial blood gases during the surgical preparation,
the injury production, and acute cerebral hemodynamic
monitoring. Surgical preparations included placement of a
femoral or tail arterial catheter for monitoring blood pressure
and withdrawing blood samples, placement of a femoral ve-
nous catheter for administering fluid and/or drugs, and a
craniectomy for producing a lateral cortical impact injury and
for monitoring intracranial pressure (ICP) with a Codman
microsensor catheter ( Johnson & Johnson, Raynham, MA)
and cerebral blood flow with a Periscan PIM3 laser Doppler
imager (Perimed, Stockholm, Sweden). The craniotomy was
10 mm in diameter, centered over the right parietal cortex
between bregma and lambda. An impact injury of 3 m/sec,
2.5 mm deformation was induced using a pneumatic impactor
device. The tip of the impactor was 8 mm in diameter and
rounded. The impact was directed at an angle perpendicular
to the surface of the brain.
For the ‘‘hemorrhage phase’’, which lasted 50 min, the an-
esthesia was isofluorane in room air to mimic the conditions
of injury in the field. A blood volume of 2.0 mL/100g body
weight, which was usually sufficient to reduce mean arterial
pressure (MAP) to *40 mm Hg, was withdrawn through the
femoral catheter. Half of this volume was withdrawn within
5 min, then 25% was withdrawn over the next 5 min, and the
final 25% was withdrawn over the next 5 min. This deceler-
ating rate of blood loss mimics the clinical situation. If this
volume of blood did not achieve the desired MAP, an addi-
tional amount in 0.5 mL over 5 min was withdrawn. The total
time of this injury phase lasted 50 min (i.e., injury + hemor-
rhage during the first 15 min, followed by 35 min of un-
resuscitated hypotension).
The second phase of ‘‘pre-hospital care’’, which consisted of
fluid resuscitation, lasted for 30 min. During this time, lac-
tated Ringer’s solution was infused in 1 mL boluses to achieve
a MAP of at least 50 mm Hg.
The third phase of ‘‘definitive hospital care’’, which con-
sisted of blood resuscitation and drug treatment, also lasted
for 30 min. During this time, the anesthesia was switched to
isoflurane in 100% oxygen, and the shed blood was re-
infused. At the end of the blood re-infusion, at 110 min post-
injury, the assigned drug treatment was administered.
In the chronic experiments, after the animal was fully re-
suscitated, the isofluorane was discontinued. Escape, right-
ing, head support, corneal, pinna, paw, and tail reflexes were
assessed every minute for half an hour once the rats were
extubated and breathing spontaneously following termina-
tion of anesthetic (Dixon et al., 1991). When fully awake, the
animals were returned to their cages and allowed free access
to food and water. The animals were given butorphanol tar-
trate 0.05 mg subcutaneously every 12 h for analgesia, and
enrofloxacin 0.05mL/kg subcutaneously every 12 h to pre-
vent postoperative infections for 3 days post-injury.
End point assessments
MAP, ICP, and laser Doppler blood flow (LDF) were
monitored throughout the experiment, at 10 min intervals
until blood re-infusion and then every 30 min during the 2 h
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post-treatment monitoring period. At each time point, the
LDF measurements were summarized for the contusion core
at the impact site, for penumbra brain surrounding the impact
site, and for uninjured parietal cortex in the hemisphere
contralateral to the impact site. The rectal temperature and
brain temperature were kept at 37–37.5C throughout the
experiment.
Tests of motor strength and coordination and tests of
memory and learning were performed. These included:
1. Beam balance test. The animal was placed on a narrow
wooden beam, and the duration of time that the animal
could maintain balance on the beam, up to 60 sec, was
recorded. Three trials per day just prior to injury and on
days 1–5 post-injury were performed.
2. Beam walking test. Two days prior to the impact injury,
the animals was trained to escape a bright light and
loud, white noise by traversing a narrow wooden beam
(2.5 · 100 cm) to enter a darkened goal box at the op-
posite end of the beam. During this training and testing,
the animal was placed initially in the goal box for 30 sec,
then at the entrance to the goal box at which time the
noise and light were turned on and then terminated
when the mouse entered the goal box. The animal was
placed at one of five distances further away from the
goal box until it could successfully run down the beam
from the position close to the source of light and noise.
Then they learned to run down the beam with four
plastic pegs (4.0 cm high) placed in an alternating se-
quence along the beam to increase the difficulty of the
task. Performance was assessed by measuring the time
required for the animal to traverse the beam. The ani-
mals remained in the goal box for 30 sec between trials.
Three trials just prior to injury and on days 1–5 post-
injury were performed.
3. Morris Water Maze test. This test measured post-injury
learning and memory for the position of a 10 cm circular
clear Plexiglas platform hidden 2 cm below the surface
of white opaque water in a 5 foot diameter white cir-
cular water tank. The platform was placed in the
northwest position throughout the test. The animal was
placed in the pool facing the wall of the tank at one of
four directions: north, south, east, or west according to
a different order for each day that was fixed across all
animals. If the animal did not find the platform in
120 sec, the animal was placed on the platform for
30 sec. If the animal was not able to swim and keep its
head out of the water, it was removed from the tank
immediately. If the animal attempted to get off the
platform, it was placed back on it. Different visual cues
were present on each wall of the room that allowed the
animal to learn the position of the platform relative to
the cues. Four trials were performed with 4 min for rest
between trials on post-injury days 11–15. The animal
was kept warm under a heating lamp between trials.
For each trial, performance was assessed by measuring
the time required for the animal to find the platform,
and by the percent of the time spent swimming in the
quadrant containing the platform.
On day 15 after the last behavioral test was performed, the
animals were deeply anesthetized and perfused via the right
ventricle with 0.9% saline, followed by 4% paraformaldehyde.
The entire brain was removed and fixed in a buffered 30%
sucrose solution overnight. Following sucrose infiltration and
immediately prior to subsequent processing, an 18 gauge
needle was inserted ventrally on the left side of the brain from
rostral-to-caudal position. Brains were frozen and sectioned
in the coronal plane on a Hacker Instruments Cryostat at a
tissue thickness of 30 lm. Sections were sequentially placed in
48 well-plates in a tris-buffered/polyethylene glycol solution
to maintain tissue integrity when stored at - 20C. Every
ninth section was collected and immediately mounted, in
sequential order, onto gelatin-coated slides and dried on a
slide warmer.
Mounted sections were stained with hematoxylin and eosin
(H&E), dehydrated, and coverslipped. Slides were then
scanned on an Epson Expression 1680 scanner driven by
Adobe Photoshop CS3 at a resolution of 1200 dpi. Lesion
volumes were determined using ImageJ software. Briefly,
after establishing scale, the lesion cavity was outlined and
filled, generating the lesion area per section. The lesion vol-
ume per animal was subsequently determined as the sum of
the area measurement of each section times the thickness of
the section (30 lm) times the sampling interval.
Every ninth section was collected and immunolabeled with
a monoclonal antibody raised against the pan-neuronal
marker NeuN (Millipore) using established immunofluores-
cent techniques. Briefly, sections were incubated in anti-NeuN
antibody overnight at 4C at a concentration of 0.75 ug/ml.
NeuN immunoreactivity was visualized following incubation
with goat anti-mouse secondary conjugated to Alexa Fluor
568 (Invitrogen) for 3 h. Sections were rinsed, mounted and
coverslipped using Fluoromount-G (Fisher Scientific), an
aqueous mounting medium. Counts of NeuN-immunoreac-
tive (-IR) neurons were performed in the ipsilateral hippo-
campal CA1 and CA3 regions as follows. Six sections per
brain were examined in the coronal plane from rostral-to-
caudal extent. Images were generated using a Nikon A1R
confocal system. Individual sections were examined by eye at
20 · magnification to identify CA1 and CA3 regions of the
hippocampus ipsilateral to the lesion site. Once identified, an
image stack of 11 optical sections was generated along the
z-axis of the field of interest. Laser power, gain, and contrast
settings were maintained throughout all stages of acquisition.
The sixth, or middle optical section was saved and converted
to .TIFF format for subsequent counts of NeuN-IR profiles.
Neurons were counted in these images using Nikon’s Ele-
ments software package. Briefly, an initial threshold value
was determined, saved, and applied to all subsequent images.
Following the initial application of threshold values, addi-
tional segmentation was performed to clearly separate adja-
cent neuronal cell bodies. Counts/mm2 for each brain section
were then generated.
Treatment groups
The treatment groups in each experiment consisted of a
randomized assignment to either EPO 5000 U/kg i.v. or i.p.,
pHBSP 30 lg/kg, or control, which consisted of either saline
or an inactive peptide 30 lg/kg. The first dose of the assigned
drug was given i.v. and the subsequent doses were given i.p.
The inactive peptide sequence (ULSEARNQSEL) had the
same amino acid components as pHBSP, but in scrambled
order. The investigators conducting the injury experiment
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and the outcome measures were blinded to the treatment
assignment. The dose of pHBSP was based on previous
studies in other tissues that showed cytoprotection with doses
ranging from 1 to 60 lg/kg (Ahmet et al., 2011).
For the acute experiment, 31 animals received a single dose
of the assigned treatment (pHBSP 11 animals, EPO 9 animals,
and control 11 animals). In the chronic experiment, 56 animals
received doses of the assigned drug every 12 h for 3 days after
injury (pHBSP 19 animals, EPO 15 animals, control 22 ani-
mals).
Statistical analysis
Outcome assessments that were repeated over time, such as
the hemodynamic measurements and the behavioral tests,
were analyzed using repeated measures ANOVA. Histology
assessments were analyzed using one-way ANOVA. A post-
hoc test to adjust for multiple comparisons (such as Sidak-
Holms) was used when the main effects from the ANOVA test
were significant. The summary values in the text and figures
are the mean – standard error.
Results
Injury parameters
To assure that all animals received a similar impact injury,
the impact parameters that can be varied were monitored in
all of the experiments. In both the acute hemodynamic and the
chronic behavioral/histology experiments, there were no
differences in these impact characteristics among the experi-
mental groups.
Recovery of the righting reflex post-injury is sometimes
used as a measure of the initial injury, being analogous to the
human loss of consciousness. For the animals in the chronic
experiment, reflex recovery time (in minutes) after the post-
injury termination of anesthetic did not vary significantly
across treatment groups for escape, head support, righting,
corneal, pinna, paw, and tail reflexes ( p > 0.4 for all reflexes).
This neurological finding supports the impact velocity data
indicating that the initial injury was similar in all treatment
groups.
Acute hemodynamic changes
The changes in cerebral perfusion pressure (CPP) and LDF
are illustrated in Figure 1. The p values from the repeated
measures ANOVA for the effects of treatment group and of
time, as well as for the treatment by time interaction, are given
in each graph. When the treatment by time interaction was
significant, symbols indicate which individual points were
significantly different between the treatment groups. Data for
ICP and MAP during the different experimental time periods
are summarized in Table 1.
MAP fell from 77 – 1 mm Hg at baseline to a nadir of
42 – 1 mm Hg during the hemorrhagic shock period, and then
recovered to 61 – 1 mm Hg with fluid resuscitation and to
75 – 1 mm Hg with the definite resuscitation that included re-
infusion of blood. There were no differences in MAP between
treatment groups at baseline, during hemorrhagic shock, or
during resuscitation. However, following administration of
the drug treatments, the EPO- and pHBSP-treated animals
had better preservation of blood pressure than the controls
(treatment effect, p = 0.002; time effect, p < 0.001; time · treat-
ment interaction, p < 0.001). At the end of the monitoring
period, MAP averaged 77 – 2 mm Hg in the pHBSP-treated
animals, and 76 – 3 mm Hg in the EPO-treated animals,
compared to 65 – 2 mm Hg in the control animals ( p < 0.05,
Holm-Sidak test).
ICP followed a similar pattern to the MAP, but the differ-
ences between the treatment groups were not significant
during any time period, and ICP values in all treatment
groups remained within normal values. ICP fell from
7.8 – 0.3 mm Hg at baseline to a low of 4.2 – 0.2 mm Hg dur-
ing the hemorrhagic shock period. ICP increased then to
8.3 – 0.3 mm Hg with fluid resuscitation, and then to 10.3 –
0.3 mm Hg following re-infusion of blood.
CPP, calculated from the difference between MAP and ICP,
was 69 – 1 mm Hg at baseline, and fell to a low of 38 – 1 mm
Hg during the period of hemorrhagic hypotension. Following
fluid resuscitation, CPP increased to 53 – 1 mm Hg. With re-
infusion of blood, CPP increased further to 65 – 1 mm Hg. The
post-resuscitation and post-treatment CPP was significantly
better in the EPO-treated and the pHBSP-treated animals than
in the control animals (treatment effect, p = 0.502; time effect,
p < 0.001; time · treatment interaction, p = 0.014). At the end of
the monitoring period, CPP averaged 66 – 2 mm Hg in
the pHBSP group, 65 – 2 mm Hg in the EPO group, compared
to 56 – 2 mm Hg in the control animals ( p < 0.05, Holm-
Sidak test).
The LDF values were normalized to the pre-injury levels
for each brain site. Treatment effects for LDF were greatest in
the core contusion region of the brain. Changes in LDF in the
core contusion site fell from 100% to a low value of 39 – 3%
during hemorrhagic shock, and then recovered partially to
60 – 2% with fluid resuscitation, and to 72 – 2% following
reinfusion of blood. Following infusion of the assigned drug
treatment, LDF in the core contusion began to fall in the
control group to a low at the end of the monitoring period of
43 – 4% of the baseline values. In contrast, the LDF in the core
contusion continued to improve following the drug treat-
ment in the pHBSP-treated group to 88 – 4%, and remained
constant at 74 + 4% of the baseline values in the EPO-treated
group at the end of the monitoring period. LDF values in the
penumbra area surrounding the core contusion followed the
same pattern as in the core. LDF values on the contralateral
side had less severe reduction in values during the hemor-
rhagic shock period, and better recovery following resusci-
tation of blood pressure, but little difference between the
treatment groups.
Chronic assessments
As is illustrated in Figure 2, the injury that resulted from the
mild cortical impact injury followed by hemorrhagic hypo-
tension was loss of cortical tissue at the site of the impact. Both
drug treatments resulted in a 70% reduction in the volume of
contused tissue at 2 weeks post-injury. Contusion volume
averaged 20.8 – 2.8 mm3 in the control groups compared to
7.7 – 2.0 mm3 in the EPO-treated group and 5.9 – 1.5 mm3 in
the pHBSP-treated group (Fig. 3) ( p = 0.001). As is shown in
Figure 4, the reduction in the injured tissue occurred
throughout the brain with EPO and pHBSP, but was greatest
in the center of the injury site.
In contrast to the cortex, the hippocampus underlying the
impact site remained well preserved in the control animals,
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and there was not a significant difference between the
treatment groups in the cell counts from the CA1 and CA3
regions of the hippocampus. For the CA3 region, the cell
count averaged 50.2 – 2.3 cells/mm2 for the control animals,
compared to 54.2 – 1.6 cells/mm2 for the EPO-treated ani-
mals and 54.3 – 1.4 cells/mm2 in the pHBSP-treated animals
( p = 0.226).
Weight of the rats decreased after the injury with the lowest
values 8.7% below baseline on post-injury day 1. Thereafter
weight gradually increased and surpassed the pre-injury level
FIG. 1. The cerebral hemodynamic response to the impact injury (first arrow) followed by 50 min of hemorrhagic hypo-
tension (shock), 30 min of fluid resuscitation (pre-hospital resuscitation), 30 min of blood re-infusion and oxygen therapy
(hospital resuscitation), administration of the assigned drug treatment (second arrow), and 2 h of post-treatment monitoring.
The numbers of animals in each group are given in the figure legend . The results of the repeated measures ANOVA test are
summarized in each graph. When the group · time interaction was significant, symbols indicate which treatments were
significantly different among the treatment groups by Holm-Sidak post-hoc test. CPP, cerebral perfusion pressure; LDF, laser
Doppler flow.
Table 1. Intracranial Pressure (ICP) and Mean Arterial Pressure (MAP)









ICP-controls 7.5 – 0.9 4.4 – 0.8 6.8 – 0.9 8.6 – 1.2 8.6 – 1.2
-EPO 6.7 – 0.7 4.6 – 0.4 8.1 – 1.1 10.8 – 2.1 11.5 – 1.9
-pHBSP 9.0 – 1.1 5.1 – 0.6 9.6 – 1.3 11.0 – 1.4 11.4 – 1.6
MAP-controls 75.9 – 1.4 41.2 – 1.3 61.3 – 1.3 71.0 – 2.3 65.2 – 2.0
-EPO 75.8 – 1.8 42.6 – 0.6 57.7 – 2.3 76.1 – 2.2 76.1 – 3.0*
-pHBSP 79.3 – 1.9 41.9 – 0.5 63.2 – 1.8 77.8 – 1.8 77.1 – 1.6*
An asterisk indicates the values that are significantly different from the control group.
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FIG. 2. (A) Representative images of the injured hemisphere for the three treatment groups, showing sizeable contusion in
the control animal (left panel), and much smaller contusions in the EPO-treated (middle panel) and the pHBSP-treated animal
(right panel). (B) Representative appearance of cortical neurons around and under the lesion site in EPO-treated (middle
panel) and ARA290-treated (right panel) animals, compared to the normal distribution of neurons observed in the contra-
lateral uninjured cortex (left panel). The arrows indicate areas where NeuN-positive neurons were detected. The images were
captured using widefield fluorescence imaging. The scale bar indicates 200 lm. (C) Representative appearance of cortical
neurons around and under the larger lesion site of saline-treated animals, using widefield fluorescence imaging. The arrows
show areas at the edge of the contusion cavity where NeuN- positive neurons were detected. The scale bar indicates 200 lm.
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by day 15. Weight did not vary significantly by treatment
group or days (the day of injury, compared to days 1–5 and
11–15 post-injury).
For the beam balance task, all of the rats balanced on the
beam for the 60 sec duration of each of the 3 trials immedi-
ately prior to the injury; therefore, data prior to the injury
were not included in the model used to analyze the data. The
best fit model for the beam balancing data included the in-
dependent variables ‘‘treatment group’’ and ‘‘days post-in-
jury’’. Performance on the task improved significantly over
days 1–5 post-injury ( p < 0.001) as might be expected with
recovery of function. The pHBSP ( p < 0.001) and EPO
( p < 0.001) treatment groups balanced significantly longer on
the beam than the control group after taking into account the
day effect. The data for each group over days is represented
in Figure 5.
Only rats who met the final pre-injury criterion of walking
down the beam in £ 5 sec on three consecutive trials were
involved in the experiment. This produced very little vari-
ability in the beam walking time for the three trials just prior
to injury. Only data from performance on the three trials for
days 1–5 post-injury were therefore included in the analysis.
The best fit model for the beam walking data involved the
independent variables ‘‘treatment group’’ and ‘‘days post-
injury’’. Performance on the task improved significantly over
days 1–5 post-injury in all groups ( p < 0.001) with beam
walking time decreasing over days. This is to be expected with
FIG. 3. Mean contusion volume at 2 weeks post-injury for
the three treatment groups. EPO and pHBSP both resulted in
a 70% decrease in contusion volume. The p value is the result
from the ANOVA test. An asterisk indicates the groups that
are significantly different from the control group ( p < 0.05)
after adjusting for multiple comparisons by the Holm-Sidak
method.
FIG. 4. Area of contusion on serial brain slices from anterior to posterior. The brain slices were 30 lm thick and every ninth
slice was examined for a total of 24 slices for each animal. Each point in the graph represents the average contusion area of the
animals in each treatment group for the individual slice. The contusion areas were analyzed by repeated measures ANOVA
with treatment group and brain slice as factors (treatment group effect, p < 0.001; treatment group · slice interaction, p < 0.001).
An asterisk indicates the slices where the EPO- and pHBSP- treated groups were significantly different from the control group
by Holm-Sidak post-hoc test.
FIG. 5. Results for the beam balance test. The beam balance
duration is the time that the animals were able to balance on
a narrow beam. All animals were able to balance for 60 sec
on Day 0, which is prior to the injury, and all treatment
groups improved significantly over time ( p < 0.001). The
animals treated with EPO ( p < 0.001) and pHBSP ( p < 0.001)
were able to balance for significantly longer post-injury than
were the control animals, after adjusting by day.
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recovery of function over days. The pHBSP ( p < 0.001) and
EPO ( p = 0.010) treatment groups walked significantly faster
on the beam than the control group after adjusting by day. The
data for each group over trials and days is represented in
Figure 6.
The model that best fit the Morris Water Maze latency data
included weight, treatment group, day, and trial. Weight on
days 11–15 proved to be related to latency in finding the
platform; therefore, the data were corrected for this covariate.
With this correction, there were no significant differences
between the treatment groups in their latency to find the
platform. Latency decreased significantly over trials
( p < 0.001) and days ( p < 0.001), as expected.
When the hidden platform was removed from the tank
after the last (fourth) learning and memory trial of day 15, the
percentage of time spent swimming in the platform quadrant
provided a measure of memory for where the platform
should have been. This time was similar for the treatment
and control groups. The platform was put back in the tank in
its previous position for a visible platform trial. A piece of
Plexiglas was added to the top of the platform so as to make
it visible above the water. Latency (seconds) to swim to
the visible platform was similar across treatment groups
indicating no differences in using visual cues to find the
platform.
Discussion
Cytoprotection with EPO after trauma
In the early 1990s, the first observations of EPO-induced
in vitro trophic effects, and of the presence in central nervous
system tissues of EPOR as well as local EPO production fol-
lowing hypoxia, were reported (Digicaylioglu et al., 1995; Ko-
nishi et al., 1993; Marti et al., 1996; Masuda et al. 1993). In 2000,
Brines and associates demonstrated that systemically admin-
istered recombinant human EPO (rhEPO) could cross the
blood–brain barrier and reduce the size of injury in animal
models of stroke and TBI (Brines et al., 2000). Since that time,
many laboratories have shown that EPO possesses tissue pro-
tective effects in different tissues and organs, including the
heart, kidney, and immune system. Multiple pathways that
might have neuroprotective effects are activated in the brain by
EPO after a brain injury. EPO decreases neuronal apoptosis,
improves blood–brain barrier integrity and reduces brain
edema. In addition, EPO has anti-inflammatory, neurotrophic,
angiogenic and synaptogenic activities, and has been shown to
promote the recruitment of stem cells after injury.
Some clinical studies also suggest that there is cytoprotection
with EPO. Zarychanski and associates (2007) published a meta-
analysis of nine clinical trials of rhEPO in critically ill patients
for the treatment of anemia of critical illness. The total number
of patients in these trials was 3314, and the overall odds ratio
for mortality was 0.86 ( p = 0.14). Two trials (EPO-2 and EPO-3)
contributed most of the patients to this analysis (Corwin et al.,
2002, 2007). Although there was not a clear survival benefit
with rhEpo for all patients enrolled in either study, rhEPO did
have a significantly improved mortality rate for the subgroup
of patients who had traumatic injuries in both studies. For the
EPO-2 study, this subgroup analysis was post hoc. For the
EPO-3 study, this was a planned subgroup analysis with
stratification of treatment by admission diagnosis category
(medical, surgical, or trauma) (Napolitano et al., 2008).
Of the total 1423 trauma patients enrolled in the EPO-2
study (n = 630) and the EPO-3 study (n = 793), most had some
degree of brain injury, but 456 (32%) had a severe TBI defined
by an admission Glasgow Coma Score (GCS) £ 8. Mortality
rate in those trauma patients with GCS £ 8 was 6.6% (15/229)
in the placebo-treated group, and 4% (9/227) in the EPO-
treated group (Napolitano et al., 2008).
Despite the improvement in the outcome of the EPO-
treated patients, there was a significant increase in the inci-
dence of thrombophlebitis, from 5.7% to 8.7% ( p = 0.04)
(Corwin et al., 2007). The concern about thromboembolic
complications with EPO, which are dose-related (Dicato,
2008), has limited the translation of EPO as a neuroprotective
agent. Development of a drug that would have the neuro-
protective effects of EPO without these hematologic compli-
cations would be a significant advance in TBI treatment, both
civilian and military. The present studies suggest that pHBSP
may have these characteristics.
Cytoprotection with EPO derivatives
The molecular interaction of EPO with the homodimer
erythropoietic receptor complex [(EPOR)2] is well studied.
Critical regions within the EPO molecule that interact with
(EPOR) 2 have been identified, and include portions of helices
A and C (site II) as well as helix D and the loop connecting
helices A and B (site I) (Elliott et al., 1997).
Chemical or mutational modification of amino acid resi-
dues within sites I and II on the EPO molecule eliminates its
ability to bind to (EPOR)2. Some of these modified EPO
molecules, including carbamylated EPO (CEPO), retain tissue
protective properties (Leist et al., 2004). CEPO has been re-
ported to have neuroprotective activities similar to EPO in a
variety of experimental injury models including TBI, stroke,
and spinal cord injury (Adembri et al., 2008; King et al., 2007;
Mahmood et al., 2007; Wang et al., 2007; Xiong et al., 2010).
FIG. 6. Results for the beam walking test. The beam crossing
time is the length of time required to traverse the narrow
beam. All animals were able to accomplish this task within
5 sec on Day 0 prior to the injury, and all treatment groups
improved significantly over time ( p < 0.001). The animals
treated with EPO ( p = 0.010) and pHBSP ( p < 0.001) were
significantly faster in crossing the beam post-injury than
were the control animals, after adjusting by day.
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The receptor mediating the cytoprotective effects of such
EPO derivatives is thought to be pharmacologically distinct
from (EPOR)2. Brines and associates proposed that the re-
ceptor that promotes tissue protection is a heteromer com-
posed of two EPOR monomers and two molecules of CD131,
also referred to as the beta common receptor (Brines et al.,
2004). Brines and Cerami recently reviewed the characteristics
of this proposed tissue protective receptor (Brines and Cer-
ami, 2008). First, the receptor has a low affinity for EPO
(1–20 nmol/L). As a result, it does not respond to EPO at the
1–7 pmol/L concentrations normally present in the circula-
tion. It is probable that it is activated only by high levels of
locally produced EPO. Additionally, the tissue protective re-
ceptor is not usually expressed until after an injury occurs,
and only requires a brief exposure to EPO to trigger sustained
biological activity. This is in contrast to (EPOR)2, which is
normally expressed in hematopoietic cells, and requires sus-
tained levels of EPO to support erythropoiesis.
pHBSP is an 11 amino acid peptide composed of the adja-
cent amino acids in space on the aqueous face of helix B of
EPOR. It was designed to mimic the tertiary structure of helix
B (Brines et al., 2008). In previous studies, it has provided
neuroprotection in models of sciatic nerve compression, and
stroke (Brines et al., 2008). It has also been demonstrated to
have cardioprotective effects (Ueba et al., 2010).
Experimental TBI model
The model used for these experiments consists of a mild TBI
and a period of hypotension induced by withdrawal of blood.
This mild cortical impact injury alone causes minimal if any
histological consequences (Cherian et al., 1999). However,
when the mild cortical impact injury is followed by a period of
hemorrhagic hypotension, the resulting cortical contusion is
equivalent to a severe cortical impact injury. This injury sce-
nario models the polytrauma patient who has also sustained a
mild TBI.
Previous studies have suggested that this magnification of
brain injury in the mild cortical impact injury model followed
by a secondary insult is caused by a severe reduction in blood
flow at the impact site, which does not occur in sham-injured
animals with the same secondary insult (Giri et al., 2000).
Similar findings have been observed with secondary insults
following fluid percussion injury (Matsushita et al., 2001). For
this reason, the cerebral hemodynamic effects of the drug
treatment were especially pertinent.
Both EPO and pHBSP provided a similar preservation
of blood flow in the core of the contusion but also in penumbra
tissue surrounding the core following resuscitation. Studies in
subarachnoid hemorrhage have suggested that EPO improves
cerebral pressure autoregulation (Springborg et al., 2002). This
characteristic of EPO might provide better blood flow during
periods of hypotension. As the drug treatment in the present
study was not given until after resuscitation was complete, the
beneficial effects did not alter the actual severity of ischemia
that occurred during the period of hemorrhagic hypotension,
but instead must have modified consequences of reperfusion
injury. For this reason, it cannot be concluded whether the
observed hemodynamic effects contributed to the improved
outcome or if these findings simply reflected better preserva-
tion of brain tissue via some other cytoprotective action. Fur-
ther studies will be needed to clarify this.
EPO and pHBSP also resulted in better recovery of blood
pressure following resuscitation. It is possible that this con-
tributed to the improved perfusion that was observed fol-
lowing resuscitation; however, the actual increases in cerebral
perfusion pressure were quite modest, as ICP was also
slightly higher.
The plasma half-life of pHBSP in rats is* 2 min (Brines et al.,
2008). Despite this short half-life in the circulation, it is equally
as cytoprotective on a molar basis as EPO. This characteristic
implies that pHBSP has a rapid effect on gene expression. In
vitro models demonstrate that a brief exposure to EPO for as
little as 5 min is sufficient to initiate neuroprotective activities
(Morishita et al., 1997). Another derivative of EPO (asialo EPO)
has a similar in vivo neuroprotective effect to EPO even though
it has a very short plasma half-life of a few minutes (Erbayr-
aktar et al., 2003). An important consequence of a short half-life,
however, might be that the time of administration could be
more critical than with an agent having a longer half-life. In the
current study, the treatment with pHBSP was started after re-
suscitation from hemorrhagic hypotension. This time was
chosen because it was thought that reperfusion injury was
probably a major component of the brain injury in this model.
Further studies would be needed to determine if treating earlier
or later would have the same effect.
Choice of anesthetic might have played a role in the out-
come of the study. Isofluorane was used as the anesthetic
throughout the injury–hypotension paradigm, and baseline
and resuscitation blood pressures were somewhat lower than
normal as a result. The findings might have been different if
another anesthesia had been used.
Conclusion
Administration of pHBSP and EPO had similar neuropro-
tective effects, reducing contusion volume and improving
some aspects of neurobehavioral outcome, in this model of
mild TBI complicated by hemorrhagic hypotension. As
pHBSP has not been observed to have the adverse thrombo-
genic effects of EPO, it may prove to be a better neuropro-
tective agent for patients with TBI.
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